Key result
Ticagrelor 60 mg twice daily provided similar platelet inhibition to 90 mg in elderly ACS patients, with pre-dose PRU differences of -8.80 in diabetics and 0.01 in non-diabetics (interaction p=0.48).
Why the study?
Data were lacking on the pharmacodynamic and pharmacokinetic profile of low-dose versus standard-dose ticagrelor during the early phase after ACS according to diabetic status.
Does ticagrelor 60 mg twice daily provide similar platelet inhibition compared to 90 mg twice daily in elderly ACS patients undergoing PCI, irrespective of diabetic status?
Does ticagrelor 60 mg twice daily provide similar platelet inhibition compared to 90 mg twice daily in elderly ACS patients undergoing PCI, irrespective of diabetic status?
Ticagrelor 60 mg twice daily provides comparable platelet inhibition to the standard 90 mg dose in elderly ACS patients, regardless of diabetic status, despite lower plasma drug levels.
No takes yet. Share an insight, caveat, or question.
May permit lower ticagrelor dosing in elderly ACS to reduce bleeding; extends PD evidence irrespective of diabetes.
Laino et al. (2026) studied this question. Ticagrelor 60 mg twice daily provided similar platelet inhibition to 90 mg in elderly ACS patients, with pre-dose PRU differences of -8.80 in diabetics and 0.01 in non-diabetics (interaction p=0.48).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: